Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M21,264Revenue (TTM) $M1,702Net Margin (%)-6.6Altman Z-Score9.5
Enterprise Value $M20,668EPS (TTM) $-0.5Operating Margin %0.6Piotroski F-Score4
P/E(ttm)--Beneish M-Score-2.5Pre-tax Margin (%)-4.0Higher ROA y-yY
Price/Book15.910-y EBITDA Growth Rate %--Quick Ratio2.4Cash flow > EarningsY
Price/Sales12.45-y EBITDA Growth Rate %--Current Ratio2.5Lower Leverage y-yN
Price/Free Cash Flow424y-y EBITDA Growth Rate %--ROA % (ttm)-4.3Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-10.7Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M248ROIC % (ttm)2.9Gross Margin Increase y-yN

Gurus Latest Trades with VRTX

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

VRTX is held by these investors:

VRTX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Arbuckle Stuart AEVP\Chief Commercial Officer 2017-02-13Sell3,792$88.39-3.01view
ALTSHULER DAVIDEVP, Global Research and CSO 2017-02-13Sell6,403$87.68-2.22view
LEIDEN JEFFREY MCEO & President 2017-02-13Sell23,904$87.68-2.22view
Sachdev AmitEVP, CRO 2017-02-13Sell7,684$87.68-2.22view
Chodakewitz JeffreyEVP GMDA, CMO 2017-02-13Sell5,122$87.67-2.21view
SMITH IAN FEVP, CFO & COO 2017-02-13Sell3,842$87.66-2.2view
Parini MichaelEVP, CLO & CAO 2017-02-01Sell3,450$85.98-0.29view
Chodakewitz JeffreyEVP GMDA, CMO 2017-02-01Sell1,900$85.74-0.01view
BOGER JOSHUA SDirector 2017-01-11Sell8,000$82.483.94view
BOGER JOSHUA SDirector 2017-01-04Sell6,500$77.1311.15view

Quarterly/Annual Reports about VRTX:

    News about VRTX:

    Articles On GuruFocus.com
    Galapagos NV Tests Cystic Fibrosis Treatment on First Patient Feb 03 2017 
    Galapagos NV Announces Results From Cystic Fibrosis Treatment Study Dec 27 2016 
    Piotroski F-Score in the Real World Dec 19 2016 
    Testing of Treatment for Cystic Fibrosis Patients Begins Nov 29 2016 
    Edward Owens Top 2nd Quarter Investments Aug 03 2016 
    Vanguard Health Care Fund Ups Stake in High-Conviction Stocks May 10 2016 
    Vanguard Boosts Stake in Incyte in 1st Quarter May 02 2016 
    Kyle Bass Sells Stakes in 11 Health Care Companies Mar 01 2016 
    Lee Ainslie Adds 90 New Stocks to His Portfolio Within the First Quarter May 20 2015 
    Analysts Confident That Vertex Pharmaceuticals' CF Drug Will Receive FDA Approval May 13 2015 

    More From Other Websites
    Headcount at ​Vertex surges in 2016, hitting four-year high Feb 23 2017
    VERTEX PHARMACEUTICALS INC / MA Files SEC form 10-K, Annual Report Feb 23 2017
    Zacks.com featured highlights: Ets, Incyte, Abercrombie & Fitch, Vertex Pharmaceuticals and... Feb 13 2017
    5 Toxic Stocks to Dump or Play Short for Gains Feb 09 2017
    Premarket Biotech Movers: Neurocrine Biosciences, Aralez Pharmaceuticals, Qiagen Jan 27 2017
    Biotech M&A Activity Expected to Rise in 2017: Latest Reports on Exelixis and Vertex Pharmaceuticals Jan 27 2017
    Blog Coverage Celgene Acquires Delinia; Set to Expand Inflammation and Immunology Portfolio Jan 27 2017
    Vertex Pharmaceuticals, Inc. :VRTX-US: Earnings Analysis: Q4, 2016 By the Numbers : January 26, 2017 Jan 26 2017
    Vertex Pharma's (VRTX) Q4 Earnings & Sales Beat; Stock Up Jan 26 2017
    Edited Transcript of VRTX earnings conference call or presentation 25-Jan-17 9:30pm GMT Jan 25 2017
    Vertex tops Street 4Q forecasts Jan 25 2017
    Vertex tops Street 4Q forecasts Jan 25 2017
    [$$] Vertex Pharmaceuticals Swings to Profit Jan 25 2017
    VERTEX PHARMACEUTICALS INC / MA Files SEC form 8-K, Results of Operations and Financial Condition,... Jan 25 2017
    Vertex Reports Full-Year and Fourth-Quarter 2016 Financial Results Jan 25 2017
    The Zacks Analyst Blog Highlights: RedHill Biopharma, Cempra, Vertex Pharmaceuticals, Acorda... Jan 25 2017

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)